You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Larry Spitcaufsky | 117,054 | 35,238 | 117,054 | 35,238 | 152,292 | 6.04% |
Page 1 of 5 – SEC Filing
Chanticleer Holdings, Inc. |
(Name of Issuer) |
Common Stock, Par Value $0.0001 per share |
(Title of Class of Securities) |
15930P404 |
(CUSIP Number) |
Larry Spitcaufsky P.O. Box 891 Rancho Santa Fe, California 92067 858-759-4443 |
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
August 25, 2017 |
(Date of Event which Requires Filing of this Statement) |
Follow Sonnet Biotherapeutics Holdings Inc. (NASDAQ:SONN)
Follow Sonnet Biotherapeutics Holdings Inc. (NASDAQ:SONN)
Page 2 of 5 – SEC Filing
CUSIP No. 15930P404 |
1 | NAME OF REPORTING PERSON: | ||||
Larry Spitcaufsky | |||||
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) | (a) | ☐ | ||
(b) | ☐ | ||||
3 | SEC USE ONLY | ||||
4 | SOURCE OF FUNDS (SEE INSTRUCTIONS): | ||||
OO | |||||
5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E): | ☐ | |||
6 | CITIZENSHIP OR PLACE OF ORGANIZATION: | ||||
United States of America | |||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER: | |||
117,0541 | |||||
8 | SHARED VOTING POWER: | ||||
35,2382 | |||||
9 | SOLE DISPOSITIVE POWER: | ||||
117,0541 | |||||
10 | SHARED DISPOSITIVE POWER: | ||||
35,2382 | |||||
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: | ||||
152,292 | |||||
12 | CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): | ☐ | |||
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): | ||||
6.04% (based on 2,474,302 shares of Common Stock issued and outstanding as of May 11, 2017 as reported in Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 15, 2017 and adjusted for the Issuer’s 1 for 10 reverse stock split on May 19, 2017, and determined in accordance with Rule 13d-3 of the Exchange Act). | |||||
14 | TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): | ||||
IN | |||||
Follow Sonnet Biotherapeutics Holdings Inc. (NASDAQ:SONN)
Follow Sonnet Biotherapeutics Holdings Inc. (NASDAQ:SONN)
Page 3 of 5 – SEC Filing
Follow Sonnet Biotherapeutics Holdings Inc. (NASDAQ:SONN)
Follow Sonnet Biotherapeutics Holdings Inc. (NASDAQ:SONN)
Page 4 of 5 – SEC Filing
Item 1. | Security and Issuer. |
Item 2. | Identity and Background. |
(c) | Mr. Spitcaufsky also currently serves as a member of the board of directors of the Issuer. |
Item 3. | Source and Amount of Funds or Other Consideration. |
Item 4. | Purpose of Transaction. |
Item 5. | Interest in Securities of the Issuer. |
Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer. |
Item 7. | Material to be Filed as Exhibits. |
Follow Sonnet Biotherapeutics Holdings Inc. (NASDAQ:SONN)
Follow Sonnet Biotherapeutics Holdings Inc. (NASDAQ:SONN)
Page 5 of 5 – SEC Filing
Date: August 30, 2017 | ||
Larry Spitcaufsky | ||
/s/ Larry Spitcaufsky | ||
Larry Spitcaufsky |